Article ; Online: Tocilizumab.
2009 Volume 1, Issue 5, Page(s) 432–438
Abstract: Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product ... ...
Abstract | Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease. |
---|---|
MeSH term(s) | Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Arthritis, Rheumatoid/drug therapy ; Castleman Disease/drug therapy ; Clinical Trials as Topic ; Crohn Disease/drug therapy ; Drug Administration Schedule ; European Union ; Humans ; Japan ; Mice ; Receptors, Interleukin-6/immunology ; Treatment Outcome ; United States |
Chemical Substances | Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Receptors, Interleukin-6 ; tocilizumab (I031V2H011) |
Language | English |
Publishing date | 2009-09-10 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2537838-7 |
ISSN | 1942-0870 ; 1942-0870 |
ISSN (online) | 1942-0870 |
ISSN | 1942-0870 |
DOI | 10.4161/mabs.1.5.9497 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.